Innoviva (INVA) Competitors

Innoviva (NASDAQ:INVA) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, community ranking, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Which has higher valuation & earnings, INVA or ALKS?

Alkermes has higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$369.84M	3.68	$179.72M	-$1.01	-21.48
Alkermes	$1.51B	3.25	$367.07M	$2.09	14.27

Do institutionals & insiders have more ownership in INVA or ALKS?

99.1% of Innoviva shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 2.3% of Innoviva shares are held by insiders. Comparatively, 4.4% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the media favor INVA or ALKS?

In the previous week, Alkermes had 5 more articles in the media than Innoviva. MarketBeat recorded 10 mentions for Alkermes and 5 mentions for Innoviva. Alkermes' average media sentiment score of 0.87 beat Innoviva's score of 0.65 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alkermes	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend INVA or ALKS?

Innoviva currently has a consensus price target of $55.00, suggesting a potential upside of 153.57%. Alkermes has a consensus price target of $38.85, suggesting a potential upside of 30.23%. Given Innoviva's stronger consensus rating and higher probable upside, equities analysts plainly believe Innoviva is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Alkermes	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.77

Which has more volatility and risk, INVA or ALKS?

Innoviva has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500.

Does the MarketBeat Community favor INVA or ALKS?

Alkermes received 400 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 70.18% of users gave Alkermes an outperform vote while only 57.52% of users gave Innoviva an outperform vote.

Company	Underperform	Outperform
Innoviva	Outperform Votes 306 57.52%	Underperform Votes 226 42.48%
Alkermes	Outperform Votes 706 70.18%	Underperform Votes 300 29.82%

Is INVA or ALKS more profitable?

Alkermes has a net margin of 23.57% compared to Innoviva's net margin of 18.31%. Alkermes' return on equity of 30.80% beat Innoviva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	18.31%	20.84%	11.38%
Alkermes	23.57%	30.80%	19.09%

Summary

Alkermes beats Innoviva on 14 of the 19 factors compared between the two stocks.